We have treated the first ex-US patient in our global clinical trial program evaluating our IL-6 receptor antibody for patients hospitalized with severe COVID-19. The US trial, led by Regeneron, already initiated earlier this month, and ex-US trials run by Sanofi initiated in several countries including Italy, Spain, Germany, France, Canada and Russia. Read the full announcement here: https://bit.ly/2WVvNr0
Great news!!! Promising!!!! Keep it rolling. All the best!
Rob Cahill
Hello Lisa. Super posting.
hoping for success!
Testing for the 13 markers all highly related to clinical manifestations of the inflammatory process is streamlined. We would like to collaborate on using our 13 marker microarray. The added information will be very helpful in guiding treatment and certainly in monitoring dosing of drugs to reduce the inflammatory response. Can we schedule time to talk? leahamir@vantageview.com 314-458-7552.
Crazy!
do you need a consultant writer? I have worked in vaccine and infectious disease of Pfizer for many years. Please let me know.
GLOBAL MEDICAL AFFAIRS LEADER Endocrinology, Diabetes & Metabolism Hemophilia Transplant 2021 NNI CMR Award Recipient 2023 NNI Best Collaborator Award Recipient
4yWishing you much success!!